Viracta Therapeutics to Host Key Opinion Leader Webinar
Virtual KOL event to focus on the unmet medical need in relapsed/refractory EBV-positive lymphoma and the design of NAVAL-1, a global pivotal trial
Event to take place on Thursday, May 20th at 2:00 PM ET
News provided by
Share this article
Share this article
SAN DIEGO, May 18, 2021 /PRNewswire/ Viracta Therapeutics, Inc. (Nasdaq: VIRX) (Viracta), a precision oncology company targeting virus-associated malignancies, will host a key opinion leader (KOL) webinar on nanatinostat and valganciclovir for the treatment of relapsed/refractory Epstein-Barr virus (EBV)-positive lymphoma on Thursday, May 20, 2021 at 2:00 PM ET.
The call will feature a presentation by KOLs
Viracta Therapeutics to Host Key Opinion Leader Webinar prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
National Cancer Institute-designated Sidney Kimmel Cancer Center partners with Caris’ collaborative network of oncology experts to advance personalized cancer treatments
IRVING, Texas, May 14, 2021
– Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced today that the Sidney Kimmel Cancer Center – Jefferson Health (SKCC) has joined Caris’ Precision Oncology Alliance™ (POA). The POA is a collaborative network of leading cancer centers that work together to advance comprehensive cancer profiling and establish standards of care for molecular testing in oncology through research focused on predictive and prognostic markers that improve the clinical outcomes of patients with cancer.
Calculator That Predicts Risk of Lung Cancer Underperforms in Diverse Populations
Research finds that a commonly used risk-prediction model for lung cancer does not accurately identify high-risk Black patients who could benefit from early screening
Getty Images
May 5, 2021 Lung cancer is the third most common cancer in the U.S. and the leading cause of cancer death, with about 80% of the total 154,000 deaths recorded each year caused by cigarette smoking. Black men are more likely to develop and die from lung cancer than persons of any other racial or ethnic group, pointing to severe racial disparities. For example, research has shown that Black patients are less likely to receive early diagnosis and life-saving treatments like surgery. Now researchers at Jefferson have found that a commonly used risk prediction model does not accurately identify high-risk Black patients who could gain life-saving benefit from early screening, and paves the way for improving screenings and gu
Risk prediction model does not accurately identify lung cancer risks in diverse population
Lung cancer is the third most common cancer in the U.S. and the leading cause of cancer death, with about 80% of the total 154,000 deaths recorded each year caused by cigarette smoking. Black men are more likely to develop and die from lung cancer than persons of any other racial or ethnic group, pointing to severe racial disparities.
For example, research has shown that Black patients are less likely to receive early diagnosis and life-saving treatments like surgery.
Now researchers at Jefferson have found that a commonly used risk prediction model does not accurately identify high-risk Black patients who could gain life-saving benefit from early screening, and paves the way for improving screenings and guidelines. The research was published in